MDR1基因多态性对相关药物药动学影响研究进展

摘要/Abstract

摘要： 药物在体内的处置通常是由转运蛋白参与完成的。其中的P-糖蛋白(P-gp),由多药耐药基因MDR1编码,其作用是加速药物从这些组织的外排。MDR1基因多态性直接影响P-gp的分布和功能,并影响着P-gp底物药物的体内处置。因此对于不同基因型编码的P-gp的生理和生化功能的进一步研究对个体化药物治疗非常重要。本文就目前研究较多的MDR1基因单核苷酸多态性对不同底物的药动学影响进行了综述,为临床个体用药提供一定的参考。

关键词: MDR1, 基因多态性, P-糖蛋白, 药动学

Abstract: Transport proteins involve in drug disposition in vivo. P-glycoprotein, encoded by multidrug resistance1, accelerates the drug efflux from those tissues.MDR1 gene polymorphisms not only has an direct influence on the distribution and function of P-gp, but also has an impact on the disposition of its substrates.Further study of physiological and biochemical function on different genetype encoding P-gp could be very important in individual treatment.This article reviews recent studies of influence of single nucleotide polymorphisms of MDR1 gene on the pharmacokinetics of substrates and this can provide references for clinical individualized therapy.

Key words: MDR1, Gene polymorphisms, P-glycoprotein, Pharmacokinetics

中图分类号:

R968

丁征, 邓婕, 宋洪涛. MDR1基因多态性对相关药物药动学影响研究进展[J]. 中国临床药理学与治疗学, 2011, 16(10): 1191-1196.

DING Zheng, DENG Jie, SONG Hong-tao. Advances in the influence of MDR1 gene polymorphisms on pharmacokinetics of related drugs[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(10): 1191-1196.

参考文献

[1] Li YH,Wang YH,Li Y,et al. MDR1 gene polymorphisms and clinical relevance[J]. Acta Genet Sinica,2006,33(2):93-104.
[2] Hoffmann U,Kroemer HK. The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance[J]. Drug Metab Rev,2004,36(3/4):669-701.
[3] 许景峰. 药物基因组学应用于临床药学是个体化用药的必然趋势[J]. 药学服务与研究,2009,9(3):161-165.
[4] 徐萍,李焕德. 多药耐药基因MDR1多态性的研究进展[J]. 中国临床药理学杂志, 2006,22(6):464-467.
[5] Kung KL,Gottesman MM. A synonymous polymorphism in a common MDR1(ABCB1) haplotype shapes protein function[J]. Biochimt Biophys Acta,2009,1794(5):860-871.
[6] Jeannesson E,Siest G,Bastien B,et al. Association of ABCB1 gene polymorphisms with plasma lipid and apolipoprotein concentrations in the STANISLAS cohort[J]. Clin Chim Acta,2009,403(1/2):198-202.
[7] Mahadevan D,List AF. Targeting the multidrug resistance-1 transporter in AML:molecular regulation and therapeutic strategies[J]. Blood,2004,104(7):1940-1951.
[8] Chen S,Huo X,Lin Y,et al. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients[J]. Int J Hyg Environ Health,2010,213(2):140-145.
[9] Pal D,Mitra AK. MDR- and CYP3A4-mediated drug-herbal interations[J]. Life Sci,2006,78(18):2131-2145.
[10] Hoffmeyer S,Burk O,Von Richter C,et al. Functional polymorphisms of the human multidrug-resistance gene:multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo[J]. Proc Natl Acad Sci U S A,2000,97(7):3473-3478.
[11] Kurata Y,Leiri I,Kimura M,et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, s substrate of P-glycoprotein[J]. Clin Pharmacol Ther,2002,72(2):209-219.
[12] Tanabe M,Ieiri I,Nagata N,et al. Expression of P-glycoprotein in human placenta:relation to genetic polymorphism of the multidrug resistance(MDR)-1 gene[J]. Pharmacol Exp Ther,2001,297(3):1137-1143.
[13] 范秀珍,郭歆,王华杰. MDR1基因C3435T多态性对替米沙坦血药浓度及降压疗效的影响[J]. 中国临床药理学与治疗学,2009,14(6):24-27.
[14] Min DI,Lee M,KU YM,et al. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers[J]. Clin Pharmacol Ther,2000,68(5):478-486.
[15] Von Ahsen N,Richter M,Grupp C,et al. No Influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism(CYP3A4-V allele)on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients[J]. Clin Chem,2001,47(6):1048-1052.
[16] Barnard JB, Richardson S, Sheldon S, et al. The MDR1/ABCB1 gene, a high-impact risk factor for cardiac transplant rejection[J]. Transplantation,2006,82(12):1677-1682.
[17] Zheng H, Zeevi A, Schuetz E, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms[J]. Am J Transplant,2003,3(4):477-483.
[18] Xie HG. Personalized immunosuppressive therapy in pediatric heart transplantation:Progress, pitfalls and promises[J]. Pharmacol Ther,2010,126(2):146-158.
[19] 张亚同,杨莉平,邵宏,等. MDR1基因C3435T多态性对重症肌无力患者环孢素血药浓度的影响[J]. 中国临床药理学与治疗学,2005,10(2):133-136.
[20] Kwan P,Brodie MJ. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy[J]. Epilepsia,2005,46(2):224-235.
[21] Siddiqui A,Kerb R,Weale ME,et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1[J]. N Engl J Med,2003,348(15): 1442-1448.
[22] Tan NC,Heron SE,Scheffer IE,et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy[J]. Neurology,2004,6(6):1090-1092.
[23] Sills GJ,Mohanraj R,Butler E,et al. Lack of association between the C3435T polymorphism in the human multidrug resistance(MDR1)gene and response to antiepileptic drug treatment[J]. Epilepsia,2005,46(5):643-647.
[24] Hendrickson SL,Jacobson LP,Nelson GW,et al. Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-free survival[J]. J Acquir Immune Defic Syndr,2008,48(3):263-271.
[25] Fellay J,Marzolini C,Meaden ER,et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter1:a pharmacogenetics study[J]. Lancet,2002,359(9300):30-36.
[26] Kedmi M,Maayan S,Cohen SB,et al. MDR1 and CYP3A4 polymorphisms are associated with HIV seropositivity in Israeli patients but do not influence the course of HIV disease[J]. AIDS Patient Care STDS,2007,21(9):653-658.
[27] Boulton DW,Devane CL,Liston HL,et al. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics[J]. Life Sci,2002,71(2):163-169.
[28] Bozina N,Kuzman MR,Medved V,et al. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients[J]. J Psychiatr Res,2008,42(2):89- 97.
[29] Yasui-Furukori N,Saito M,Nakagami T,et al. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients:A preliminary study[J]. Prog Neuropsychopharmacol Biol Psychiatry,2006,30(2):286-291.
[30] Peles AM,Bozina N,Sagud M,et al. MDR1 gene polymorphism:therapeutic response to paroxetine among patients with major depression[J]. Prog Neuropsychopharmacol Biol Psychiatry,2008,32(6):1439-1444.
[31] Kirschbaum KM,Henken S,Hiemke C,et al. Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice[J]. Behav Brain Res,2008,188(2):298-303.
[32] Kastelic M,Koprivsek J,Plesnicar BK,et al. MDR1 gene polymorphisms and response to acute risperdone treament[J]. Prog Neuropsychopharmacol Biol Psychiatry,2010,34(2):387-392.
[33] Kim RB,Leake BF,Choo EF,et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans[J]. Clin Pharmacol Ther,2001,70(2):189-199.
[34] 毛晓琴,谢海棠,周宏灏. 多药耐药蛋白和CYP3A4介导的中草药-西药相互作用[J]. 中国临床药理学与治疗学,2007,12(7):728-734.
[35] Breedveld P,Beijnen JH,Schellens JH. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs[J]. Trends Pharmacol Sci,2006,27(1):17-24.